

Response Under 37 CFR 1.116
Expedited Procedure - Examining Group 1600
Application No. 10/031,509
Paper Dated: December 18, 2004
In Reply to USPTO Correspondence of August 18, 2004
Attorney Docket No. 702-020040

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-52 (Cancelled).

Claim 53 (Currently Amended): A method for [the preparation of a composition for] inhibiting renal uptake of proteins and peptides used for therapeutic or diagnostic purposes [and] that possibly may be damaging to the kidneys of a subject, comprising:

[providing] administering [the] a combination of two amino acids: a first amino acid which is a lysine selected from the group consisting of D-lysine, L-lysine and poly-lysine, or a pharmaceutically acceptable salt or carboxylic acid derivative thereof; and a second amino acid which is selected from the group consisting of arginine and ornithine, or a pharmaceutically acceptable salt or carboxylic acid derivative thereof,

wherein the first amino acid is [provided] administered in an amount of about [10-45] 15-35 grams per treatment and the second amino acid is [provided] administered in an amount of about 15-[45]35 grams per treatment.

Claim 54 (Canceled)

Claim 55 (Previously Presented): The method of claim 53, wherein the first amino acid is provided in an amount of about 20-30 grams and the second amino acid is provided in an amount of about 20-30 grams per treatment.

Response Under 37 CFR 1.116
Expedited Procedure - Examining Group 1600
Application No. 10/031,509
Paper Dated: December 18, 2004
In Reply to USPTO Correspondence of August 18, 2004
Attorney Docket No. 702-020040

Claim 56 (Previously Presented): The method of claim 53, wherein the first amino acid is provided in an amount of about 25 grams and the second amino acid is provided in an amount of about 25 grams per treatment.

Claim 57 (Previously Presented): The method of claim 53, wherein the second amino acid is arginine.

Claim 58 (Currently Amended): A therapeutic composition for [the inhibition of the] inhibiting renal uptake of protein or peptides used for therapeutic or diagnostic purposes that possibly may be damaging to the kidneys of a subject, comprising one or more pharmaceutically acceptable excipients, carriers or diluents and a combination of:

a first amino acid which is a lysine selected from the group consisting of D-lysine, L-lysine and poly-lysine, or a pharmaceutically acceptable salt or carboxylic acid derivative thereof; and

a second amino acid which is selected from the group consisting of arginine and ornithine, or a pharmaceutically acceptable salt or carboxylic acid derivative thereof,

wherein the first amino acid is provided in an amount of about [10-45] 15-35 grams per treatment, and the second amino acid is provided in an amount of about 15-[45]35 grams per treatment.

Claim 59 (Canceled)

Claim 60 (Previously Presented): The therapeutic composition of claim 58, wherein the first amino acid is provided in an amount of about 20-30 grams and the second amino acid is provided in an amount of about 20-30 grams per treatment.

Response Under 37 CFR 1.116
Expedited Procedure - Examining Group 1600
Application No. 10/031,509
Paper Dated: December 18, 2004
In Reply to USPTO Correspondence of August 18, 2004
Attorney Docket No. 702-020040

Claim 61 (Previously Presented): The therapeutic composition of claim 58, wherein the first amino acid is provided in an amount of about 25 grams and the second amino acid is provided in an amount of about 25 grams per treatment.

Claim 62 (Previously Presented): The therapeutic composition of claim 58, wherein the second amino acid is arginine.

Claim 63 (Previously Presented): The therapeutic composition of claim 58, wherein the first amino acid and the second amino acid or their respective derivatives thereof are present in about 1 L infusion fluid.

Claim 64 (Canceled)